期刊
ONCOGENE
卷 30, 期 39, 页码 4118-4128出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/onc.2011.118
关键词
EZH2/MEK-ERK pathway; histone; triple negative; breast cancer; ERBB2-overexpressing breast cancer
资金
- Ministry of Education, Culture, Sports, Science and Technology, Japan [21590453]
- Grants-in-Aid for Scientific Research [21590453] Funding Source: KAKEN
EZH2 overexpression occurs in various malignancies and is associated with a poor outcome. We have so far demonstrated that EZH2 downregulates the important genes such as E-cadherin and RUNX3 by increasing histone H3K27 trimethylation. However, the mechanism of EZH2 overexpression in various cancer cells remains unclear. In this study we carried out a promoter analysis of the EZH2 gene and investigated whether a survival signal that is upregulated in cancer cells is related to overexpression at the transcription level. We also explored the clinical relevance of the signaling pathway that leads to EZH2 overexpression in breast cancer and demonstrated that MEK-ERK1/2-Elk-1 pathway leads to EZH2 overexpression. The triple-negative and ERBB2-overexpressing subtypes of breast cancer are known to contain more rapidly proliferating breast cancer cells. The signaling pathway connected to EZH2 overexpression was associated with both aggressive subtypes of breast cancer. We show the significance that overexpression of histone modifier protein EZH2 in cancer cells and our study could pave the way for EZH2 inhibition to become an efficient treatment for more aggressive breast cancers. Oncogene (2011) 30, 4118-4128; doi:10.1038/onc.2011.118; published online 18 April 2011
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据